Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

INBX•2026-07-16

Oxford Finance facility expanded to USD 500 million

Inhibrx Biosciences entered a second amendment to its loan and security agreement with Oxford Finance, expanding the credit facility to USD 500 million.

The new tranche adds up to USD 325 million; USD 100 million was funded at signing as a Term C Loan.

Up to USD 225 million more is available as a Term D Loan in USD 50 million minimum draws, subject to lenders’ discretion.

The company had already drawn USD 175 million under the facility before the amendment.

Lenders received warrants for 21,457 shares at a USD 93.21 strike price, equal to 2% of the Term C Loan value.

Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

Oxford Finance facility expanded to USD 500 million

Related News

Relay Therapeutics Inc <RLAY.O>: Canaccord Genuity initiates coverage with buy rating; price target $29

Rockwell Automation selected as control platform provider for Aalo Atomics’ Aalo-X test reactor

US pending home sales slump in June amid affordability challenges

T3 Defense announces 1-for-125 reverse stock split effective July 20

Nasdaq trade halt continues <PLTS.O> reason not available at 09:33 AM